The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Treatment of Prostate Cancer with Gonadotropin-Releasing Hormone Agonists
Abstract
It is now well established that chronic treatment with GnRH agonists offers an advantageous alternative to orchiectomy and estrogens for the treatment of prostate cancer. Castration levels of androgens can thus be easily achieved without side effects other than those related to castration levels of serum androgens. However, man is unique among species in having a high secretion rate of precursor adrenal steroids which are converted into active androgens in the normal prostate and prostatic cancer. All the enzymes required for the transformation of dehydroepiandrosterone sulfate, dehydroepiandrosterone, androstenedione, and androst-5-ene-3 beta, 17 beta-diol are present in prostatic tissue. Moreover, as shown in many systems, castration levels of serum testosterone (T) at 0.2-0.4 ng/ml exert significant androgenic activity in target tissues. In order to inhibit the action of androgens of both testicular and adrenal origin, GnRH agonists have been administered in association with the pure antiandrogen Flutamide in patients having clinical stage D2 (bone metastases) prostate cancer. A positive objective response assessed according to the criteria of the United States National Prostatic Cancer Project (USNPCP) has been observed in 84 of the 88 patients who had received no previous treatment (95.4%). After 2 yr of treatment, the probability of continuing response is 70% compared to 0-10% by previous approaches. In addition, the death rate at 2 yr is at 10.9% as compared to approximately 50% after standard hormonal therapy. When the same treatment was applied to patients who had received previous hormonal therapy (orchiectomy, estrogens or GnRH agonists alone) before showing a relapse, the response rate decreased to 62.9% and the death rate at 2 yr was 52%.(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Geller, J., Albert, J. D., Nachtsheim, D. A., & Loza, D. (1984) · Journal of Urology · doi:10.1016/s0022-5347(17)49829-6 · Cited by 98
Cited by
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Labrie, F., Bélanger, A., Cusan, L., Gomez, J.-L., & Candas, B. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.8.4160 · Cited by 713
Self-citationLabrie, F. (1991) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(91)90116-a · Cited by 685
Self-citationGonadotropin-releasing hormone and its analogues
Desforges, J. F., Conn, P. M., & Crowley, W. F. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101103240205 · Cited by 470
GONADOTROPIN-RELEASING HORMONE AND ITS ANALOGS
Conn, P. D., & Crowley, W. F. (1994) · Annual Review of Medicine · doi:10.1146/annurev.med.45.1.391 · Cited by 459
Metadata
- Authors
- LABRIE, F., DUPONT, A., BÉLANGER, A., ST-ARNAUD, R., GIGUÈRE, M., LACOURCIÈRE, Y., EMOND, J., & MONFETTE, G.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 1986-02
- Volume
- 7
- Issue
- 1
- Pages
- 67-74
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2072685254
- Cited by
- 179
- References
- 1
- FWCI
- 28.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Prostate Cancer with Gonadotropin-Releasing Hormone Agonists. https://app.cochat.ai/papers/10.1210/edrv-7-1-67
- The paper
- LABRIE, F., DUPONT, A., BÉLANGER, A., ST-ARNAUD, R., GIGUÈRE, M., LACOURCIÈRE, Y., EMOND, J., & MONFETTE, G. (1986). Treatment of Prostate Cancer with Gonadotropin-Releasing Hormone Agonists. Endocrine Reviews. https://doi.org/10.1210/edrv-7-1-67
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.